SNBL Clinical Pharmacology Center Inc.

SNBL Clinical Pharmacology Center Inc. is a research organization specializing in clinical pharmacology, offering innovative solutions for drug development and testing services to the pharmaceutical industry. Founded in 2006 and headquartered in Baltimore, US, SNBL Clinical Pharmacology Center Inc. provides vital support to pharmaceutical companies in their drug development processes.

The firm has participated in one deal, with the most recent transaction occurring on February 28, 2017. The company has not undergone any notable business pivots or changes since its inception. SNBL Clinical Pharmacology Center Inc. specializes in clinical trials and pharmacokinetic studies, offering comprehensive research services tailored to the pharmaceutical industry.

The firm provides a range of services, including bioanalytical testing, Phase I clinical trials, and consulting, designed to assist clients in meeting regulatory requirements and optimizing drug development strategies. Their expertise serves a diverse clientele, from small biotech firms to large pharmaceutical companies, focusing on ensuring the efficacy and safety of new therapeutics. The company generates revenue primarily through its clinical research services, which are billed on a project basis. This pricing model accommodates various client needs, ranging from small studies to large-scale clinical trials.

Additionally, revenue is supplemented through consulting services that support clients in navigating complex regulatory landscapes. The firm maintains strong relationships with its clients, contributing to repeat business and sustained income streams. SNBL Clinical Pharmacology Center Inc. plans to enhance its service offerings by developing new clinical trial protocols and expanding its bioanalytical capabilities.

The company is actively targeting new markets, particularly in Europe and Asia, with plans to establish partnerships in these regions by the end of 2024. The funding raised in February 2017 from Pharmaron Holding Limited will be utilized to support these expansion initiatives and bolster their research infrastructure, ensuring the company remains competitive in the evolving clinical research landscape.